Aiming at an ‘Undruggable” target, Pyrotech’s class 1 small-molecule candidate gets approved for sepsis clinical trials
On August 4, Pyrotech Therapeutics (“Pyrotech”) announced that its independently developed small-molecule pyroptosis inhibitor, PTT-121, has been approved for clinical trials in China, intended for the treatment of sepsis and septic shock.…
Alphamab Oncology and Pathos reach international licensing agreement for TROP2/HER3 bispecific ADC.
On August 4, Alphamab Oncology (“Alphamab”) announced a licensing agreement with Pathos AI (“Pathos”) for its proprietary, “First-in-Class” TROP2/HER3 bispecific antibody-drug conjugate (ADC), JSKN016. Under the…
Kelun Biotech seeks marketing approval on sac-TMT for the first-line treatment of PD-L1-negative TNBC
On July 30, 2026, Sichuan Kelun Biotech Co., Ltd. (“Kelun”) announced that its independently developed antibody-drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2), sac-TMT (also known as SKB264/MK-2870) (Gitalay®), has…